Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$4.05
+0.8%
$3.15
$2.12
$5.80
$402.78M1.971.49 million shs433,186 shs
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$4.26
$4.23
$2.06
$4.50
$370.71M1.181.53 million shsN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.33
0.0%
$6.80
$4.58
$9.78
$367.48M1.89486,808 shs109,606 shs
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
$2.08
+0.7%
$2.02
$1.15
$42.20
$100.24M-2.042.86 million shs213,202 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-0.25%+9.24%+17.54%+60.80%+45.13%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.00%0.00%0.00%+5.45%+69.72%
CryoPort, Inc. stock logo
CYRX
CryoPort
-2.27%-3.55%+9.90%+30.66%-1.35%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-4.63%-0.96%+0.49%+47.14%-83.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
2.1044 of 5 stars
3.53.00.00.03.40.00.0
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
0.4658 of 5 stars
1.20.00.04.21.80.00.0
CryoPort, Inc. stock logo
CYRX
CryoPort
2.096 of 5 stars
3.41.00.00.01.13.30.6
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
4.2605 of 5 stars
3.33.00.04.72.70.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
3.00
Buy$10.14150.19% Upside
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.33
Hold$4.331.72% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.75
Moderate Buy$10.8848.38% Upside
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
2.50
Moderate Buy$54.502,526.51% Upside

Current Analyst Ratings Breakdown

Latest SAVA, CKPT, AQST, and CYRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/7/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $10.00
6/17/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/2/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$7.00
5/15/2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/8/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
5/5/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $7.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
4/16/2025
CryoPort, Inc. stock logo
CYRX
CryoPort
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
$54.23M7.43N/AN/A($0.66) per share-6.14
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
$41K9,041.59N/AN/A($0.47) per share-9.06
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.61N/AN/A$7.44 per share0.99
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/A$3.03 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$44.14M-$0.59N/AN/AN/A-100.02%N/A-50.31%8/5/2025 (Estimated)
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$51.85M-$1.29N/AN/AN/AN/A-659.07%8/11/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
-$24.34M-$1.50N/AN/AN/AN/A-87.72%-72.05%8/14/2025 (Estimated)

Latest SAVA, CKPT, AQST, and CYRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.02N/AN/AN/A$7.28 millionN/A
8/5/2025Q2 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.18N/AN/AN/A$11.32 millionN/A
8/5/2025Q2 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.20N/AN/AN/A$41.74 millionN/A
5/13/2025Q1 2025
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A
5/12/2025Q1 2025
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
-$0.17-$0.24-$0.07-$0.24$12.23 million$8.72 million
5/8/2025Q1 2025
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A-$0.48N/A-$0.48N/AN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/AN/AN/AN/AN/A
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
N/A
4.87
4.48
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
N/A
0.29
0.29
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
N/A
9.08
9.08

Institutional Ownership

CompanyInstitutional Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
32.45%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
22.00%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
38.05%

Insider Ownership

CompanyInsider Ownership
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
7.85%
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
2.10%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.10%
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
12.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aquestive Therapeutics, Inc. stock logo
AQST
Aquestive Therapeutics
16099.33 million91.53 millionOptionable
Checkpoint Therapeutics, Inc. stock logo
CKPT
Checkpoint Therapeutics
1087.02 million47.81 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.07 millionOptionable
Cassava Sciences, Inc. stock logo
SAVA
Cassava Sciences
3048.31 million42.41 millionOptionable

Recent News About These Companies

Cassava Sciences Inc.
Cassava takes next step for African AI

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aquestive Therapeutics stock logo

Aquestive Therapeutics NASDAQ:AQST

$4.05 +0.03 (+0.85%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Checkpoint Therapeutics stock logo

Checkpoint Therapeutics NASDAQ:CKPT

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.33 0.00 (-0.01%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Cassava Sciences stock logo

Cassava Sciences NASDAQ:SAVA

$2.08 +0.02 (+0.73%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.